Plasma lncRNA expression profile as a prognostic tool in
BRAF inhibitor
BRAF mutation
liquid biopsy
lncRNA
melanoma
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
11 Jun 2019
11 Jun 2019
Historique:
received:
06
12
2018
accepted:
13
05
2019
entrez:
25
6
2019
pubmed:
25
6
2019
medline:
25
6
2019
Statut:
epublish
Résumé
Long non-coding RNAs (lncRNA) are dysregulated in many cancer types. Abnormal baseline levels of these lncRNAs display diagnostic and prognostic potential in cancer patients. The aim of this study was to evaluate the prognostic value of plasma lncRNAs in
Identifiants
pubmed: 31231466
doi: 10.18632/oncotarget.26989
pii: 26989
pmc: PMC6570476
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3879-3893Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare that they have no competing interests.
Références
Oncogene. 2004 Apr 19;23(18):3208-16
pubmed: 15094770
Ann Oncol. 2009 Aug;20 Suppl 6:vi1-7
pubmed: 19617292
Endocr Relat Cancer. 2013 Oct 24;20(6):R321-39
pubmed: 24080445
Lancet Oncol. 2014 Mar;15(3):323-32
pubmed: 24508103
Nucleic Acids Res. 2014 Sep;42(15):10099-111
pubmed: 25123665
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Medicine (Baltimore). 2014 Dec;93(27):e157
pubmed: 25501056
Oncotarget. 2015 Feb 10;6(4):2496-508
pubmed: 25537510
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
Cancer Res. 2015 Aug 1;75(15):3181-91
pubmed: 26069248
Int J Clin Exp Pathol. 2015 Apr 01;8(4):4008-14
pubmed: 26097588
Sci Rep. 2015 Jul 08;5:11924
pubmed: 26152796
Lancet Oncol. 2015 Oct;16(13):1389-98
pubmed: 26433819
Contemp Oncol (Pozn). 2015;19(4):280-3
pubmed: 26557775
Mol Oncol. 2016 Mar;10(3):450-63
pubmed: 26778792
Cell J. 2016 Winter;17(4):593-600
pubmed: 26862518
Oncotarget. 2017 Jun 13;8(24):38227-38238
pubmed: 27246976
Minerva Med. 2016 Oct;107(5):279-86
pubmed: 27353770
Pathol Res Pract. 2016 Aug;212(8):690-5
pubmed: 27461828
Biomed Pharmacother. 2016 Aug;82:298-303
pubmed: 27470366
J Gastroenterol Hepatol. 2017 Jun;32(6):1204-1211
pubmed: 27862275
Lancet Oncol. 2016 Dec;17(12):1743-1754
pubmed: 27864013
Biomed Pharmacother. 2017 Jan;85:218-224
pubmed: 27914827
Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5126-5131
pubmed: 28051258
Biomed Pharmacother. 2017 Mar;87:555-560
pubmed: 28081466
Oncotarget. 2017 Mar 21;8(12):19534-19546
pubmed: 28099946
Eur J Cancer. 2017 Mar;73:93-101
pubmed: 28162869
Biomark Med. 2017 Mar;11(3):277-284
pubmed: 28240100
Tumour Biol. 2017 Mar;39(3):1010428317695022
pubmed: 28349823
Contemp Oncol (Pozn). 2017;21(1):1-5
pubmed: 28435391
J Cell Biochem. 2017 May 4;:null
pubmed: 28471495
Crit Rev Oncol Hematol. 2017 Aug;116:116-124
pubmed: 28693793
Rep Pract Oncol Radiother. 2017 Sep-Oct;22(5):378-388
pubmed: 28794691
Oncotarget. 2017 May 25;8(41):69204-69218
pubmed: 29050198
Mol Cancer. 2017 Nov 13;16(1):171
pubmed: 29132362
Am J Clin Dermatol. 2018 Jun;19(3):303-317
pubmed: 29164492
Cell Cycle. 2018;17(2):154-161
pubmed: 29179614
Oncotarget. 2017 Oct 24;8(61):104160-104170
pubmed: 29262629
Mol Cancer. 2018 Jan 17;17(1):8
pubmed: 29343260
Contemp Oncol (Pozn). 2017;21(4):259-266
pubmed: 29416430
Exp Ther Med. 2018 Feb;15(2):2182-2188
pubmed: 29434823
Mol Oncol. 2018 May;12(5):648-658
pubmed: 29504701
J Dtsch Dermatol Ges. 2018 Apr;16(4):405-414
pubmed: 29512873
Mol Med Rep. 2018 May;17(5):6405-6412
pubmed: 29532866
Contemp Oncol (Pozn). 2018 Mar;22(1A):68-72
pubmed: 29628797
Eur J Hum Genet. 2018 Jul;26(7):937-945
pubmed: 29681621
Biomed Res Int. 2018 Apr 2;2018:2086564
pubmed: 29808164
Cancer Biomark. 2018;23(2):221-225
pubmed: 30198866